Can obinutuzumab help a woman with nephrotic syndrome after rituximab fails?
For a woman with nephrotic syndrome who does not respond well to rituximab, obinutuzumab is a newer anti-CD20 antibody that may offer another chance at remission. Rituximab is a standard treatment for certain types of nephrotic syndrome, but about 10% of patients show resistance or relapse despite B-cell depletion 59. Obinutuzumab is designed to cause deeper and longer-lasting B-cell depletion, which may overcome this resistance 59. Several case reports describe women who achieved complete remission after switching to obinutuzumab.
What the research says
Multiple case reports show that obinutuzumab can induce remission in patients with nephrotic syndrome who did not respond adequately to rituximab. A 2024 case report described a 37-year-old woman with frequently relapsing, steroid-dependent minimal change disease (MCD) who had only a 6-month remission with rituximab and then became resistant. After switching to obinutuzumab, she achieved and maintained complete remission for 12 months 7. Another 2026 case report detailed a 33-year-old woman with focal segmental glomerulosclerosis (FSGS) who had only partial remission with steroids and cyclosporine, and no complete remission after rituximab. Two months after receiving obinutuzumab, she achieved complete remission with normalized proteinuria and albumin levels 59. A 2026 case report also described a 54-year-old woman with membranous nephropathy who transitioned to lupus nephritis and had a rituximab infusion reaction; she achieved clinical remission with obinutuzumab 8. Additionally, a case report of a 76-year-old man with podocytopathy and a B-cell disorder showed complete remission of proteinuria and normalized kidney function within one month of obinutuzumab treatment, sustained at one year 3. These reports suggest obinutuzumab may be effective across different types of nephrotic syndrome, including MCD, FSGS, and membranous nephropathy, even after rituximab failure. However, these are individual cases, not large clinical trials, so the evidence is limited.
What to ask your doctor
- Given my history with rituximab, could obinutuzumab be a reasonable next option for my nephrotic syndrome?
- What are the potential side effects of obinutuzumab, and how do they compare to rituximab?
- How is obinutuzumab given (dose, schedule, number of infusions) and how long might it take to see results?
- Are there any ongoing clinical trials or newer treatments for nephrotic syndrome that I should consider?
- What monitoring (blood tests, urine tests) would be needed if I start obinutuzumab?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.